A Phase II Single Arm, Multi-centre Study of Bevacizumab (Avastin®) Pre- and Post-transarterial Chemoembolisation (TACE) Treatment for Localized Unresectable Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2014
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Roche
- 10 Aug 2012 Actual patient number changed from 25 to 29 as reported by ClinicalTrials.gov record.
- 10 Aug 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov record.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.